Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a Phase I/II trial in 36 evaluable patients, Doxil plus Rituxan rituximab led
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury